Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

Summary

This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and cyclophosphamide in high-risk myeloid malignancies. This is an intention to treat study, where randomization is performed at first documentation of CR after engraftment.

Timeline

Start

2024-05-22

Primary completion

2027-05

Completion

2028-05

Drugs

Indications